Stachybotrins D, Stachybocins A, Chartarlactams D、E、F 属于Phenylspirodrimanes类混源萜。Stachybotrins D对五株NNRTI耐药的HIV病毒株和野生的HIV-1具有较好的抑制作用。Stachybocins A对人类ETA和ETB受体具有抑制活性。Chartarlactams D、E、F具有降血脂作用。在Stachybotrins D的结构基础上利用拼合原理设计了5个衍生物。本课题将研究这5个天然产物和5个衍生物的全合成，同时研究衍生物的抗HIV活性。拟采用光催化的选择性活化醇上C-H键构建螺环(借助计算化学研究其立体构型)、Diels-Alder反应构建苯环等方法来实现目标化合物的合成。拟以野生HIV-1假病毒模型对所设计合成的化合物进行活性测试。探讨结构与抗HIV活性之间的关系，为生物活性高的新药做基础。

Stachybotrins D, Stachybocins A, Chartarlactams D、E、F are a family of Phenylspirodrimanes. Stachybotrins D showed an inhibitory effect on five NNRTIs resistant HIV-1 strains as well as wild-type HIV-1. Stachybocins A had the inhibitory activity of human ETA and human ETB receptors. Chartarlactams D、E、F exhibited potent lipid-lowering effects. Five new derivatives of Stachybotrins D were designed. This project focuses on the total synthesis of the five natural products and five new derivatives, meanwhile, evaluates the biological activity of derivatives. The total synthesis will be completed by highly selective photoredox α-alkylation/lactonization of alcohols with methyl acrylate、Diels-Alder reaction and theoretical calculation. The HIV-1 replication inhibition activities will be evaluated on five derivatives by recombinant VSVG/HIV-1 pseudovirions. We expacted to study the structure-relationships of anti-HIV activity and to develop high activty drugs.